Regenxbio said on Monday the U.S. Food and Drug Administration had declined to approve its gene therapy for a rare disease called Hunter syndrome, citing uncertainty regarding the trial design.

Emmanuel Macron said the meeting would be an opportunity 'to consider options for a possible release or unlocking of strategic reserves.'